Onward Medical Launches Capital Increase Through Private Placement
Onward Medical has announced the launch of a capital increase through a private placement with institutional investors, aiming to raise approximately 50 million euros.
According to the press release, Onward Medical seeks to raise gross funds of approximately 50 million euros through a private placement of new ordinary shares. The share price will be determined at the end of the book-building process.
Utilization of Funds
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
Onward Medical plans to use the net proceeds from this placement to fund various projects, including product development, clinical studies, and regulatory activities for the ARC-IM system, aimed at treating blood pressure instability in individuals with spinal cord injuries. About 40% of the funds will be allocated to these initiatives, 30% to the expansion of sales and operations to support the commercialization of the ARC-EX system, 20% to quality and administrative activities, and 10% for working capital, financial costs, and existing obligations.
Book-Building and Listing Details
The book-building period for this private placement is expected to last one business day, allowing for broader investor participation. The new shares are expected to be listed on Euronext in Brussels, Amsterdam, and Paris on October 28, 2025. The company has obtained approval from the Financial Services and Markets Authority of Belgium to temporarily suspend trading of its shares during this period.
Launch of ARC-EX continues to be a resounding success...
Risks mentioned
Retard dans les approbations réglementaires pouvant affecter les délais.
Concurrence accrue dans le secteur de la neurotechnologie.
Opportunities identified
Lancement du système ARC-EX avec succès aux États-Unis.
Récupération de la demande soutenue pour la technologie de stimulation.
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
